Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry

被引：4

作者：

Agosti, Pasquale ^{[1
]}

Leo, Pasqualina De ^{[2
]}

Capecchi, Marco ^{[3
]}

Ferrari, Barbara ^{[2
]}

Mancini, Ilaria ^{[1
]}

Gattillo, Salvatore ^{[4
]}

Trisolini, Silvia Maria ^{[5
]}

Rinaldi, Erminia ^{[6
]}

Podda, Gian Marco ^{[7
]}

Prezioso, Lucia ^{[8
]}

Salutari, Prassede ^{[9
]}

Facchini, Luca ^{[1
,10
]}

Caramazza, Domenica ^{[1
,11
]}

Tolomelli, Giulia ^{[1
,2
,12
]}

Artoni, Andrea ^{[2
]}

Peyvandi, Flora ^{[1
,2
,13
]}

机构：

[1] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy

[3] Clin Moncucco, Hematol Serv, Lugano, Switzerland

[4] Osped San Raffaele, Immuno Hematol & Transfus Med Unit, Milan, Italy

[5] Sapienza Univ Rome, Dept Translat & Precis Med, Hematol, Rome, Italy

[6] A Perrino Hosp, Hematol Unit, Brindisi, Italy

[7] Univ Milan, Dipartimento Sci Salute, ASST St Paolo & Carlo, UOC Med 2, Milan, Italy

[8] Azienda Osped Univ Parma, Haematol & BMT Unit, Parma, Italy

[9] Osped Civile Spirito Santo, Pescara, Italy

[10] Azienda USL IRCCS Reggio Emilia, Hematol Unit, Viale Umberto 1, I-42123 Reggio Emilia, Italy

[11] Univ Hosp Osped Circolo & Fdn Macchi ASST Sette La, Hematol, Viale L Borri 57, I-21100 Varese, Italy

[12] Rimini Hosp Infermi, Unit Hematol, Rimini, Italy

[13] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Dept Pathophysiol & Transplantat, Via Pace 9, I-20122 Milan, Italy

来源：

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS | 2023年 / 7卷 / 06期

关键词：

D O I：

10.1016/j.rpth.2023.102185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Caplacizumab in acquired thrombotic thrombocytopenic purpura: a profile of its use
Hannah A. Blair
Katherine A. Lyseng-Williamson
Drugs & Therapy Perspectives, 2019, 35 : 263 - 270
[22] More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
Picod, Adrien
Benhamou, Ygal
Bouzid, Raida
Veyradier, Agnes
Coppo, Paul
BLOOD ADVANCES, 2023, 7 (12) : 2678 - 2680
[23] How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
Zheng, Lucy
Zheng, X. Long
ANNALS OF BLOOD, 2023, 8
[24] How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
Zheng, Lucy
Zheng, X. Long
ANNALS OF BLOOD, 2023, 8
[25] Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
Hanlon, Ashley
Metjian, Ara
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
[26] Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
Sukumar, Senthil
George, James N.
Cataland, Spero R.
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (04) : E76 - E77
[27] Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
Cilla, Nicolas
Dallemagne, Julie
Vanhove, Marie
Stordeur, Patrick
Motte, Serge
De Wilde, Virginie
JOURNAL OF HEMATOLOGY, 2020, 9 (03) : 84 - 88
[28] Caplacizumab for the Treatment of acquired thrombotic thrombocytopenic Purpura (aTTP)
Oezcan, F.
NEPHROLOGE, 2019, 14 (06): : 470 - 472
[29] Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura
Reid, Justin H.
Durant, Karin M.
Chen, Sheh-Li
Perissinotti, Anthony J.
King, Richard
Khoriaty, Rami
Marini, Bernard L.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (07) : 1695 - 1702
[30] Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
Goshua, George
Sinha, Pranay
Hendrickson, Jeanne E.
Tormey, Christopher A.
Bendapudi, Pavan
Lee, Alfred Ian
BLOOD, 2020, 136

← 1 2 3 4 5 →